SCHEMBL13675792

SCHEMBL13675792

O=C(/C=C/c1ccc(C(F)(F)F)c(Cl)c1)Nc1ccc2ncsc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.48
KDR P35968 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
POLB P06746 1/20 0.45
GPR183 P32249 1/20 0.42
MCHR1 Q99705 6/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
HSP90AA1 P07900 1/20 0.42
PKM P14618 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
USP30 Q70CQ3 1/20 0.41
TP53 P04637 1/20 0.41
TRPV1 Q8NER1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13675819 0.84 MEN1 (0.60) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL13675829 0.79 MEN1 (0.58) MEN1KMT2ANPC1RAB9AGPR183
SCHEMBL13675632 0.78 TRPV1 (0.61) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL23510521 0.77 USP30 (0.43) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL6308840 0.76 KDR (0.67) KDRHDAC1HDAC8HDAC6MEN1
SCHEMBL3997649 0.76 TRPV1 (0.63) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL13675830 0.76 TRPV1 (0.61) NAMPTMEN1KMT2ANPC1RAB9A
SCHEMBL3997657 0.76 TRPV1 (0.63) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL3999020 0.76 MEN1 (0.54) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL3999015 0.76 MEN1 (0.54) MEN1KMT2ANPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 NAMPT 2895/4885KDR 51/4885HDAC1 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.